Shanghai Medicilon Biomedical Co., Ltd (SHA: 688202), a prominent Chinese biotech firm, has entered into separate partnerships with domestic companies Binhui Biopharmaceutical and Innoforce Pharmaceuticals Co., Ltd.
In collaboration with Binhui, Medicilon aims to explore innovative areas including oncolytic viruses, nucleic acid drugs, and protein therapeutics. Meanwhile, the partnership with Innoforce will focus on advancing RNA technologies, as well as cell and gene therapy, among other cutting-edge biotechnologies. Financial terms of either agreement were not disclosed.- Flcube.com
